New York Life Investment Management LLC acquired a new position in Glaukos Corporation (NYSE:GKOS – Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,801 shares of the medical instruments supplier’s stock, valued at approximately $1,445,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GKOS. Parallel Advisors LLC increased its position in Glaukos by 14.4% during the 3rd quarter. Parallel Advisors LLC now owns 438 shares of the medical instruments supplier’s stock valued at $72,000 after purchasing an additional 55 shares during the period. State of Wyoming raised its holdings in shares of Glaukos by 6.8% in the 3rd quarter. State of Wyoming now owns 1,030 shares of the medical instruments supplier’s stock valued at $169,000 after purchasing an additional 66 shares in the last quarter. Fulcrum Asset Management LLP raised its holdings in shares of Glaukos by 91.7% in the 3rd quarter. Fulcrum Asset Management LLP now owns 184 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 88 shares in the last quarter. Wealth Alliance LLC lifted its position in shares of Glaukos by 4.5% in the 1st quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier’s stock worth $247,000 after purchasing an additional 98 shares during the period. Finally, Abel Hall LLC lifted its position in shares of Glaukos by 3.5% in the 3rd quarter. Abel Hall LLC now owns 3,236 shares of the medical instruments supplier’s stock worth $531,000 after purchasing an additional 108 shares during the period. 99.04% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other Glaukos news, Director Gilbert Kliman sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $253.00, for a total value of $632,500.00. Following the completion of the sale, the director directly owned 37,406 shares in the company, valued at $9,463,718. This trade represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is currently owned by company insiders.
Glaukos Stock Performance
GKOS stock opened at $245.60 on Monday. The firm has a market cap of $14.54 billion, a price-to-earnings ratio of -83.54 and a beta of 0.68. The firm has a 50-day simple moving average of $184.61 and a two-hundred day simple moving average of $147.10. Glaukos Corporation has a one year low of $87.32 and a one year high of $255.18. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.09 and a current ratio of 4.57.
Glaukos (NYSE:GKOS – Get Free Report) last issued its quarterly earnings data on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.57. The firm had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The company’s quarterly revenue was up 58.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.16) EPS. On average, equities analysts forecast that Glaukos Corporation will post 0.50 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
GKOS has been the topic of several research reports. Jefferies Financial Group lifted their price objective on shares of Glaukos from $190.00 to $210.00 and gave the company a “buy” rating in a report on Tuesday, September 22nd. JPMorgan Chase & Co. boosted their price objective on shares of Glaukos from $200.00 to $240.00 and gave the stock an “overweight” rating in a research note on Thursday, October 29th. Wells Fargo & Company upped their target price on Glaukos from $178.00 to $226.00 and gave the stock an “overweight” rating in a report on Thursday, October 29th. Piper Sandler reaffirmed an “overweight” rating and set a $240.00 target price (up from $195.00) on shares of Glaukos in a research report on Thursday, October 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $216.71.
Read Our Latest Stock Analysis on GKOS
Glaukos Profile
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Further Reading
- Five stocks we like better than Glaukos
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
